Suresh Ramalingam, MD, FASCO; Winship Cancer Institute Emory University 5Live #ASCO20
5:27
Key insights on Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
Non Small Cell Lung Cancer
Suresh Ramalingam, MD, FASCO; Winship Cancer Institute Emory University 5Live #ASCO20
Key insights on Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
Non Small Cell Lung Cancer Similar Videos
Similar Videos
-
Vivek Subbiah, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO20
6:47
Key Insights on Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
-
Narjust Duma, MD; University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center; 5Live; #IASLC21
5:10
-
Suresh Ramalingam, MD, FACP, FASCO; Winship Cancer Institute of Emory University; 5Live; #IASLC21
9:26
